Commercialisation of Ayush Drugs, Technologies: New policy calls for 4 percent royalty to CCRAS
The policy focuses on the commercialisation of the various AYUSH drugs, Processes, Instrumentation that is developed by CCRAS. The various technologies are divided into three categories and will attract 4% Ex-factory Sales as royalty for the CCRAS
New Delhi: The novel ayurvedic drugs would now be accessible at pharmacies at a quicker pace. The Union minister of state for Ayush, Shripad Naik has approved the proposed policy to accelerate the commercialization procedure of technologies. This policy comprises of different categories of the products/technologies and processes need to be transferred for further commercialization.
The Central Council of Research in Ayurvedic Sciences (CCRAS), an autonomous body under Ministry of AYUSH, Govt. of India is an apex body in India for the undertaking, coordinating, formulating, developing and promoting research on scientific lines in Ayurvedic Sciences.
The council has been developing and validating drugs and technologies process at in-house Research & Development facilities and also in collaboration with reputed organizations.
Given the scenario, CCRAS prepared the guidelines that focused on transferring technology to industry, calculating royalty and resolving intellectual property rights issues. This policy has provisions for Benchmarks for undertaking research/research consultation for already commercialized/ marketed Ayurveda Products in the existing CCRAS Research Policy.
Further, the Drugs, Technologies and process etc. developed by the Council are being commercialized through National Research Development Corporation (NRDC).
In view of the expansion of the scope of R&D and its commercialization as per the provisions of CCRAS Research Policy, different categories of the products/technologies and processes need to be transferred for further commercialization.
According to the CCRAS Commercialisation Policy document technologies are grouped into three different categories;
- Category I includes independently developed technologies
- Category II includes technologies developed with collaborative efforts
- Category III includes the development of value-added technologies.
The royalty is set at 4% of ex-factory sales and the rounded premium would be calculated on a case-to-case basis depending on commercial viability and translational value.